Expanded Access Program of Surufatinib

Summary

This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications